Adverse prognosis of incidentally detected ambulatory atrial fibrillation

Thrombosis and Haemostasis

Volumn 112, Issue 2, 2014, Pages 276-286

  Martinez, Carlos ^a   Katholing, Anja ^a   Freedman, Saul Benedict ^b  

^a Institute for Epidemiology Statistics and Informatics GmbH   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; ADVERSE PROGNOSIS; AGED; AMBULATORY ATRIAL FIBRILLATION; ARTICLE; BLEEDING; BODY MASS; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; ASYMPTOMATIC DISEASE; ATRIAL FIBRILLATION; CASE CONTROL STUDY; CAUSE OF DEATH; CHEMICALLY INDUCED; EPIDEMIOLOGY; FACTUAL DATABASE; INCIDENTAL FINDING; KAPLAN MEIER METHOD; MORTALITY; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASYMPTOMATIC DISEASES; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; CAUSE OF DEATH; DATABASES, FACTUAL; FEMALE; FIBRINOLYTIC AGENTS; GREAT BRITAIN; HEMORRHAGE; HUMANS; INCIDENCE; INCIDENTAL FINDINGS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905189018     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH4-04-0383     Document Type: Article

References (42)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
2. Camm AJ, Lip GYH, Caterina RD, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
3. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764.
4. Kimura K, Minematsu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15, 831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76: 679-683.
5. Benjamin EJMDS, Wolf PAMD, D'Agostino RBP, et al. Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
6. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-2925.
7. Hannon N, Sheehan O, Kelly L, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the North Dublin population stroke study. Cerebrovasc Dis 2010; 29: 43-49.
8. Leyden JM, Kleinig TJ, Newbury J, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 2013; 44: 1226-1231.
9. Bhatt A, Majid A, Razak A, et al. Predictors of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Strokes Detected by Long-Term Noninvasive Cardiac Monitoring. Stroke Res Treatm 2011; 2100: Article ID 172074, doi 104061/2011/172074.
10. Stahrenberg RMD, Weber-Kruger M, Seegers JMD, et al. Enhanced Detection of Paroxysmal Atrial Fibrillation by Early and Prolonged Continuous Holter Monitoring in Patients With Cerebral Ischemia Presenting in Sinus Rhythm. Stroke 2010; 41: 2884-2888.
11. Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med 2012; 366: 120-129.
12. Hannon N, Sheehan O, Kelly L, et al. Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 2010; 29: 43-49.
13. Deif B, Lowres N, Freedman SB. Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int J Cardiol 2013;164: 371-372.
14. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 2010; 41: 2705-2713.
15. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
16. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2: 474-480.
17. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Followup Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663.
18. Stott DJ, Dewar RI, Garratt CJ, et al. RCPE UK Consensus Conference on 'approaching the comprehensive management of atrial fibrillation: evolution or revolution?'. J R Coll Physicians Edinb 2012; 42: 34-35.
19. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-198.
20. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
21. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; Epub ahead of print.
22. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013; 110: 213-222.
23. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
24. Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229-1235.
25. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
26. Hastie T, Tibshirami R. Generalized additive models for medical research. Stat Methods Med Res 1995; 4: 187-196.
27. Wood SN. Modelling and smoothing parameter estimation with multiple quadratic penalties. J Royal Stat Soc 2000; 62: 413-428.
28. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
30. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
31. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
32. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
33. Tsadok MA, Jackevicius CA, Rahme E, et al. Sex Differences in Stroke Risk Among Older Patients With Recently Diagnosed Atrial Fibrillation. J Am Med Assoc 2012; 307: 1952-1958.
34. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
35. Potpara TS, Polovina MM, Marinkovic JM, et al. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 2013; 168: 4744-4749.
36. Rienstra M, Vermond RA, Crijns HJ, et al. for the RI. Asymptomatic persistent atrial fibrillation and outcome: Results of the RACE study. Heart Rhythm 2014; Epub ahead of print.
37. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
38. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
39. Sjalander S, Sjalander A, Svensson PJ, et al. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014; 16: 631-638.
40. Hobbs FDR, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005; 9: iii-iv, ix-x, 1-74.
41. Lau JK, Lowres N, Neubeck L, et al. iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol 2013; 165: 193-194.
42. Lowres N, Freedman SB, Redfern J, et al. Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged >=65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. Br Med J Open 2012; 2: e0011355.